Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sameer Sharma

Urology Grafton, WI Medical Doctor

NPI 1245204197 CMS profile 825506

975 Port Washington Rd, Ste 320, Grafton, WI 53024

Open in the dashboard

General payments

$1,239

11 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sameer Sharma of Grafton, WI is reported in the CMS Open Payments database as having received $1,239 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $279 4
2023 General $581 4
2020 General $108 1
2019 General $272 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sameer Sharma
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Sameer Sharma were reported at $279. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Sameer Sharma Urology median Middle half National median
2019 $272 $480 $147–$1,201 $163
2020 $108 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $581 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $279 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $986 7 payments
  2. PROCEPT BioRobotics Corporation $149 1 payment
  3. Medtronic, Inc. $90 2 payments
  4. AbbVie, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,226 10 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Moses 550 D\F\L $423 2 payments
  2. AQUABEAM ROBOTIC SYSTEM $149 1 payment
  3. GREENLIGHT $149 1 payment
  4. rezum Generator $144 1 payment
  5. LITHOVUE $123 1 payment
  6. SPACEOAR $108 1 payment
  7. INCEPTIV $90 2 payments
  8. WaveWriter Alpha Prime 16 $40 1 payment
  9. LUPRON DEPOT $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

2,211

Median for Urology: 1,053

Drug cost

$205,616

Median for Urology: $101,464

Branded share of claims

28.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 234 $151,640
Gemtesa Vibegron Brand 47 $26,876
Tamsulosin Hcl Generic 650 $7,964
Finasteride Generic 701 $7,160
Silodosin Generic 40 $3,515
Oxybutynin Chloride Er Oxybutynin Chloride Brand 132 $2,304
Alfuzosin Hcl Er Alfuzosin Hcl Brand 84 $1,663
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 38 $636
Ciprofloxacin Hcl Generic 54 $507
Oxybutynin Chloride Generic 31 $491

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$115,812

Of which drugs: $14,122

Medicare patients

468

Average age 76

Services billed

2,265

88 women, 380 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Ischemic heart disease 37%
Chronic kidney disease 35%
Cancer 34%
Diabetes 25%
Atrial fibrillation 25%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 12 90 $11,558

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record